RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > CFDA Announces Expedited Review Process for Innovative Devices

CFDA Announces Expedited Review Process for Innovative Devices

Posted 12 February 2014 | By Louise Zornoza

The China Food and Drug Administration (CFDA) announced on 7 February 2014 the implementation of a new expedited priority review and approval process for innovative medical devices, to take effect as of 1 March 2014.

The CFDA stressed that the expedited procedure would not lower existing review and approval standards, but instead would expedite the marketing of new innovative medical device technologies. The new process is also expected to promote the research and development of innovative new medical device technologies. 

In order to qualify for the new review process, a medical device must have a patent or a patent pending, and provide a significant clinical benefit. 


Read all Breaking News from RegLink


© 2022 Regulatory Affairs Professionals Society.